Crossmark

An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression

Published Online: 2015-09-04

Published Print: 2015-09

Authors

Rice, A E

Latchman, Y E

Balint, J P

Lee, J H

Gabitzsch, E S

Jones, F R
License Information

Text and Data Mining valid from 2015-09-01

Version of Record valid from 2015-09-01
More Information

Article History

Received: 17 June 2015

Accepted: 5 August 2015

First Online: 4 September 2015

Competing interests

: AER, YL, JPB, ESG and FRJ are employees of Etubics and have equity and/or stock options in the company. JHL is a member of the Etubics Scientific Advisory Board and has stock options in the company.

Document is current